Consun Pharmaceutical Group Limited: history, ownership, mission, how it works & makes money

From its founding in 1997 in Guangzhou to its Hong Kong Main Board listing as 1681.HK in 2013, Consun Pharmaceutical Group has grown into a focused specialist in modern Chinese medicines and medical contrast media, operating four production bases across Guangzhou, Tongliao, Yulin and Horgos and reporting a 2024 revenue of RMB 2.97 billion-a 14.6% year-on-year rise-supported by a workforce of 3,164 employees (about 1.17 million HKD revenue per employee) and a dual-segment model (Consun: 85% of sales; Yulin: 15%) that powers flagship offerings like Uremic Clearance Granules (ranked on the China Medicine - Brand List Hospital Terminal for six consecutive years) while earning industry recognition such as the 2022 ESG Practice Model Award, positioning the company at the intersection of nephrology leadership, innovation-driven digitalization, green processes and targeted market monetization through product sales and academic promotion.

Consun Pharmaceutical Group Limited (1681.HK): Intro

• Founded: 1997 (Guangzhou)
• HKEX listing: 2013, stock code 1681
• Primary product lines: modern Chinese medicines, medical contrast media
• Production bases: Guangzhou, Tongliao, Yulin, Horgos

• Listing vehicle: Consun Pharmaceutical Group Limited (1681.HK) on HKEX Main Board
• Major shareholders: combination of founding entities and institutional investors (public disclosures on shareholder registry available in annual reports and HKEX filings)
• Governance: Board of directors and executive management based in Guangzhou with production management across four bases

• R&D emphasis: development of standardized, quality-controlled modern Chinese medicines
• Product diversification: traditional medicine formulations plus medical contrast agents
• Quality and compliance: GMP-aligned manufacturing across four production bases

• Primary revenue: sales of finished pharmaceutical products (traditional-modern formulations)
• Secondary revenue: contrast media sales for diagnostic imaging
• Channels: hospital procurement (tenders), pharmacy distribution, export orders

• Revenue mix typically weighted to product sales with growth driven by expanded market penetration and new product launches.
• Manufacturing capacity distributed across four facilities to manage regional demand and regulatory compliance.
• Employee growth modest (+1.18% in 2024) while revenue growth was strong (+14.6%), indicating productivity improvements or higher-value product mix.

Consun Pharmaceutical Group Limited (1681.HK): History

• Stock code: 1681.HK - publicly traded on the Hong Kong Stock Exchange.
• Jurisdiction: Incorporated in the Cayman Islands (offshore holding structure).
• Employees (as of 31 Dec 2024): 3,164.
• Revenue per employee (2024): ~1.17 million HKD; implied total revenue ~3,701.88 million HKD.
• Notable recognition: '2022 ESG Practice Model Award' (Dec 2022) for public-welfare performance.
• Industry credentials: multiple awards for innovation and academic promotion capabilities.

• R&D and product development focused on nephrology and related therapeutic areas; commercializes proprietary formulations (e.g., Uremic Clearance Granules).
• Hospital terminal sales and physician prescribing drive prescription revenue; long-standing hospital-brand recognition supports demand.
• Distribution and sales networks cover hospitals, clinics and selected retail/OTC channels, supplemented by academic promotion and KOL engagement.
• Licensing, partnerships and potential generic/adjacent-product launches diversify income streams alongside core product sales.

Consun Pharmaceutical Group Limited (1681.HK): Ownership Structure

• Core mission: provide effective medicines while balancing tradition and innovation.
• Strategic focus: nephrology as a flagship specialty plus multi-specialty expansion.
• Sustainability: green, low‑carbon processes to enhance long‑term competitiveness.
• Innovation: increased R&D, digitalization, and intelligent manufacturing to drive efficiency.

• Largest controlling shareholder (Consun Group / related holding entity): 32.5% - strategic decision influence and board control.
• Public/free float (institutional + retail): 54.0% - liquidity on HKEX 1681.HK.
• Management and insiders (executives & key employees): 13.5% - aligns management incentives with shareholders.

• Product portfolio: nephrology drugs, cardiovascular and metabolic therapies, sterile injectables, and selected OTC products-sales mix weighted toward specialty prescription medicines.
• Revenue drivers: product sales to hospitals and distributors, contract manufacturing, and export sales-hospital channel remains primary (~70% of prescription revenue).
• Profit levers: margin improvement via process automation, scale in sterile production, higher‑margin specialty drugs, and cost control through green manufacturing initiatives.
• Investment focus: R&D pipelines (nephrology and related specialties), digital transformation of supply chain and sales, and strategic M&A to expand therapeutic breadth.

Consun Pharmaceutical Group Limited (1681.HK): Mission and Values

• Core mission: integrate traditional Chinese medicine with modern pharmaceutical technology to improve clinical outcomes and expand global reach.
• Values: scientific rigor, quality compliance, innovation-led growth, efficiency, and social responsibility.

• Consun Pharmaceutical segment - modern Chinese medicines and medical contrast media (≈85% of group sales).
• Yulin Pharmaceutical segment - traditional Chinese medicines and proprietary herbal products (≈15% of group sales).

• Product sales: prescription and over-the-counter modern Chinese medicines, contrast media used in imaging diagnostics, and traditional herbal drugs sold to hospitals, clinics, distributors, and pharmacies.
• Contract manufacturing and OEM: capacity at four production bases allows third-party manufacturing and tolling services.
• R&D-driven product pipeline: new formulations and improved contrast agents command premium pricing and extended market exclusivity.
• Academic and clinical promotion: professional academic promotion enhances adoption in hospitals and specialty clinics, supporting volume and pricing.

• Strategic focus on digitalization and intelligence: production automation, ERP upgrades, and data-driven quality control to boost yield and lower unit costs.
• Structural optimization: product portfolio reshaping toward higher-margin modern Chinese medicines and contrast media.
• Industry awards: multiple recognitions for innovative capability and academic promotion strength, supporting brand and hospital channel traction.

Consun Pharmaceutical Group Limited (1681.HK): How It Works

• Primary revenue streams: sales of modern Chinese medicines (proprietary formulas) and medical contrast media.
• Key commercialization channels: hospital terminal sales, hospital procurement, distributors, and direct academic promotion to clinicians.
• Flagship product: Uremic Clearance Granules - hospital-terminal brand recognition for six consecutive years on the China Medicine - Brand List.
• Innovation & promotion: sustained investment in R&D, clinical studies and professional academic promotion that supports product adoption and pricing power.
• ESG & public welfare: recipient of the 2022 ESG Practice Model Award (Dec 2022) for public welfare performance, reinforcing reputation and stakeholder trust.

• Modern Chinese medicines: drive recurring hospital demand via chronic-disease treatment portfolios (including Uremic Clearance Granules).
• Medical contrast media: diagnostic-use products sold into radiology and imaging departments, often through tenders and institutional contracts.
• Pricing and margins: supported by product differentiation, branded hospital-terminal positioning and ongoing clinician education programs.
• Sales engine: combined in-house sales teams + distributor partners focused on hospital procurement and tender processes.

• R&D and regulatory capability - secures new product approvals and lifecycle extensions, underpinning medium-term revenue growth.
• Academic promotion - professional education and KOL engagement accelerate clinical adoption and formulary inclusion.
• Quality & compliance - manufacturing scale and GMP compliance enable hospital and institutional procurement.
• ESG and public-welfare engagement - enhances reputation and supports stakeholder alignment, as reflected in the 2022 ESG award.

Consun Pharmaceutical Group Limited (1681.HK): How It Makes Money

• Core focus: nephrology and renal supportive therapies-hospital-dominant sales model targeting nephrologists and dialysis centers.
• Product mix: patented and generic injectables, oral drugs, and biologics under in-house and licensed brands.
• Commercial capability: professional academic promotion and field sales teams driving hospital adoption and formulary listings.
• Corporate responsibility: awarded the '2022 ESG Practice Model Award' (December 2022) for public-welfare and ESG initiatives.

• High-margin hospital injectable portfolio-preferred formulary placement increases price resilience.
• Scale in nephrology-dominant clinical focus reduces commercial cost per prescription.
• R&D investment-ongoing investment in new formulations and clinical evidence to maintain competitive differentiation (company targets mid-to-high single-digit percentage of revenue toward R&D in growth years).
• Supply-chain efficiency-vertical integration in manufacturing helps control COGS and gross margins.

• Leader in Chinese nephrology segments with over two decades of industry experience and recognized innovative capability through multiple industry awards.
• Strong academic-promotion capability drives clinician adoption and repeat hospital tenders.
• ESG and public-welfare recognition-recipient of the '2022 ESG Practice Model Award' in December 2022-supports brand and stakeholder trust.
• Growth drivers: aging population, rising CKD (chronic kidney disease) prevalence, expansion of dialysis services and potential new product launches or licensing deals.